Pioglitazone/metformin

Drug Profile

Pioglitazone/metformin

Alternative Names: ACTOplus met; ACTOplus met XR; AD 48833MET; Competact; Glubrava; Metact; Metformin/pioglitazone; Metformin/pioglitazone XR

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda; Takeda Pharmaceuticals North America
  • Developer Takeda; Takeda Pharmaceuticals USA
  • Class Antihyperglycaemics; Biguanides; Small molecules; Thiazolidinediones
  • Mechanism of Action AMP activated protein kinase stimulants; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 30 Apr 2015 Launched for Type-2 diabetes mellitus in Greece and Austria (PO) before April 2015
  • 28 Aug 2014 Takeda completes a 10-year epidemiology study as part of its post-marketing commitment to submit data to the regulatory authorities in the US, EU and Japan for pioglitazone and piogliazone-containing medicines
  • 17 Aug 2012 Generic equivalent available in USA for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top